Shield Therapeutics plc (STX) Ordinary Shares 1.5p
0.50p
(5.00%)
- Add to watchlist
- Create an alert
- This stock can be held in a
0.50p
(5.00%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
0.50p
(5.00%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
10.00p
10.50p
12.35p
£101.46 million
10.00p
9.50p
2.20p
n/a
0.25p (2.44%) Previous:
0.25p
455,523
n/a
150,000
Performance
Not available for this stock.
Fundamental data
| Year ending: | 31/12/2024 | 31/12/2023 |
|---|---|---|
| Revenue (£m) | 32.18 | 13.09 |
| Profit before tax (£m) | (26.56) | (32.38) |
| Adjusted EPS (p): | (3.00) | (5.00) |
| P/E ratio | n/a | n/a |
| PEG | n/a | n/a |
| EPS growth (%) | n/a | n/a |
Values are quoted in the stock's local currency: British pound
All fundamental dataDividend information for this stock is not available.
Dividend information for this stock is not available.
Ready to invest?
Important Documents
There are no documents available for this stock.
-
FDA approves label extension for Shield's Accrufer
22 December 2025 14:58
-
Shield Therapeutics reports strongest quarterly performance to date
23 October 2025 11:56
-
Shield Therapeutics gets FDA priority review to extend Accrufer indication
4 September 2025 13:24
-
Total Voting Rights
30 January 2026 07:05
-
Approval for ACCRUFeR in China expected in Q1 2026
30 January 2026 07:00
-
Q4 2025 Trading Update
21 January 2026 07:00
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.